Literature DB >> 27583124

The relationship of management modality in Saudi patients with type 2 diabetes to components of metabolic syndrome, γ glutamyl transferase and highly sensitive C-reactive protein.

Suhad M Bahijri1, Maimoona Ahmed2, Khalid Al-Shali2, Samia Bokhari3, Amani Alhozali2, Anwar Borai4, Amani Gusti3, Ghada Ajabnoor5, Ahmed Alghamdi6, Mohammed Asiri6, Jaakko Tuomilehto7.   

Abstract

BACKGROUND: The aim of this study was to investigate the relationship among management modality, glycemic control, components of metabolic syndrome (MS) and serum levels of γ glutamyl transferase (GGT) and C-reactive protein (CRP) in patients with type 2 diabetes (T2DM).
METHODS: Patients with T2DM, not suffering from diabetes complications, were recruited from outpatients clinics at two hospitals in Jeddah. Anthropometric measurements and blood pressure (BP) were taken. A treatment plan was recorded. Fasting blood samples were obtained to measure glucose, glycated hemoglobin (HbA1c), lipids profile, highly sensitive (hs)-CRP and GGT.
RESULTS: A total of 71 men and 82 women were recruited. Lower mean HbA1c was found in people receiving oral glucose-lowering drugs compared with those on insulin therapy (p < 0.001). Management modality had no effect on mean GGT or hs-CRP. Higher mean GGT was associated with poor glycemic control, dyslipidemia, hypertension, and abdominal obesity. GGT correlated significantly (p < 0.05) and directly with triglycerides in men (r = 0.401) and diastolic BP (r = 0.279 for men, r = 0.194, for women), but inversely with high-density lipoprotein cholesterol (HDL-C) (r = -0.298 for men, r = -0.171 for women). hs-CRP correlated with waist circumference (p < 0.05, r = 0.312, for men, r = 0.305, for women), with a higher mean being found in men with poor glycemic control (p = 0.015), in hypertensive women (p = 0.030), and in patients who were abdominally obese (p < 0.05).
CONCLUSIONS: High levels of GGT and hs-CRP are associated with components of MS and poor glycemic control, hence increased cardiovascular risk. Due to their value as independent risk predictors of vascular injury, these measures should be included in routine monitoring of patients with T2DM.

Entities:  

Keywords:  highly sensitive C-reactive protein; metabolic syndrome; type 2 diabetes; γ glutamyl transferase

Year:  2016        PMID: 27583124      PMCID: PMC4994395          DOI: 10.1177/2040622316658459

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN: 2040-6223            Impact factor:   5.091


  53 in total

1.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

Authors:  M A Albert; E Danielson; N Rifai; P M Ridker
Journal:  JAMA       Date:  2001-07-04       Impact factor: 56.272

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

4.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

5.  Current practice in the management of patients with type 2 diabetes mellitus in Saudi Arabia.

Authors:  Abdulmohsen H Al-Elq
Journal:  Saudi Med J       Date:  2009-12       Impact factor: 1.484

6.  Plasma glutathione levels are independently associated with gamma-glutamyltransferase activity in subjects with cardiovascular risk factors.

Authors:  Valentina Sedda; Benedetta De Chiara; Marina Parolini; Raffaele Caruso; Jonica Campolo; Giuliana Cighetti; Renata De Maria; Aldo Sachero; Luigi Donato; Oberdan Parodi
Journal:  Free Radic Res       Date:  2008-02

7.  Visceral fat adipokine secretion is associated with systemic inflammation in obese humans.

Authors:  Luigi Fontana; J Christopher Eagon; Maria E Trujillo; Philipp E Scherer; Samuel Klein
Journal:  Diabetes       Date:  2007-02-07       Impact factor: 9.461

Review 8.  Is serum gamma glutamyltransferase a marker of oxidative stress?

Authors:  Duk-Hee Lee; Rune Blomhoff; David R Jacobs
Journal:  Free Radic Res       Date:  2004-06

9.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

10.  Coffee consumption, serum gamma-glutamyltransferase and risk of type II diabetes.

Authors:  S Bidel; K Silventoinen; G Hu; D-H Lee; J Kaprio; J Tuomilehto
Journal:  Eur J Clin Nutr       Date:  2007-03-07       Impact factor: 4.016

View more
  1 in total

1.  Elevated UMOD methylation level in peripheral blood is associated with gout risk.

Authors:  Yong Yang; Xiaoying Chen; Haochang Hu; Yuting Jiang; Hang Yu; Jie Dai; Yiyi Mao; Shiwei Duan
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.